---
title: "ARWR.US (ARWR.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ARWR.US/news.md"
symbol: "ARWR.US"
name: "ARWR.US"
parent: "https://longbridge.com/en/quote/ARWR.US.md"
datetime: "2026-05-19T21:40:06.234Z"
locales:
  - [en](https://longbridge.com/en/quote/ARWR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ARWR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ARWR.US/news.md)
---

# ARWR.US (ARWR.US) — Related News

### [Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock](https://longbridge.com/en/news/286489870.md)
*2026-05-15T01:19:54.000Z*
> Arrowhead Pharmaceuticals Director Hongbo Lu sold 2,970 shares at $76.88 each, totaling $228,333.60, reducing his stake 

### [What is HC Wainwright's Forecast for ARWR Q3 Earnings?](https://longbridge.com/en/news/286410555.md)
*2026-05-14T11:45:49.000Z*
> HC Wainwright has revised its Q3 2026 earnings estimate for Arrowhead Pharmaceuticals (NASDAQ:ARWR), lowering it to ($1.

### [Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near](https://longbridge.com/en/news/286388526.md)
*2026-05-14T09:09:24.000Z*
> Arrowhead Pharmaceuticals (NASDAQ:ARWR) is advancing its RNA interference pipeline while entering a commercial phase, as

### [Sanford C. Bernstein Boosts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $46.00](https://longbridge.com/en/news/286304606.md)
*2026-05-13T18:57:13.000Z*
> Sanford C. Bernstein has raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) from $35.00 to $46.00, main

### [Arrowhead (ARWR) Q2 2026 Earnings Transcript](https://longbridge.com/en/news/285741896.md)
*2026-05-08T14:25:17.000Z*
> The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of

### [ArrowHead Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 73.74 M](https://longbridge.com/en/news/285607988.md)
*2026-05-07T20:07:09.000Z*
### [<![CDATA[Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-PNPLA3]]>](https://longbridge.com/en/news/285390372.md)
*2026-05-06T13:19:40.000Z*
> Madrigal Pharmaceuticals and Bayer are actively engaging in mergers and acquisitions to enhance their pharmaceutical pip

### [](https://longbridge.com/en/news/285250137.md)
*2026-05-05T18:29:08.000Z*
> Arrowhead Pharma shares are trading lower. The company announced an exclusive worldwide license agreement with Madrigal